On May 20, 2014, Chimerix Inc (NASDAQ:CMRX), announced the pricing of underwritten public offering of 7.3 million shares at $14.22 per share. The company expects to close the offering on or about May 27, 2014. Chimerix Inc (NASDAQ:CMRX), weekly performance is -2.70%. On last trading day company shares ended up $16.20. Analysts mean target price for the company is $31.67. Chimerix Inc (NASDAQ:CMRX), distance from 50-day simple moving average (SMA50) is -22.34%.
Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), advanced 10.76% in last trading session and ended the day on $6.28. IMMY, return on assets is -43.50%. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), quarterly performance is -10.67%.
On May 20, 2014, Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that Actinium’s Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming educational session highlighting the role of radiopharmaceuticals, including Actimab-A, in the treatment of acute myeloid leukemia (AML) and in other cancers. The conference will be held Friday, May 30 — Wednesday June 3, 2014 at McCormick Place, Chicago, IL. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), shares moved up 7.98% in last trading session and was closed at $11.23, while trading in range of $10.20 – 11.44. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), year to date (YTD) performance is 90.66%.
Puma Biotechnology Inc (NYSE:PBYI), a development stage biopharmaceutical company, announced financial results for the first quarter ended March 31, 2014. Based on accounting principles generally accepted in the United States (GAAP), Puma reported a net loss applicable to common stock of $19.8 million, or $0.67 per share, for the first quarter of 2014, compared to a net loss of $11.8 million, or $0.41 per share, for the first quarter of 2013. Puma Biotechnology Inc (NYSE:PBYI), ended the last trading day at $65.41. Company weekly volatility is calculated as 8.00% and price to cash ratio as 23.48. Puma Biotechnology Inc (NYSE:PBYI), showed a negative weekly performance of 3.02%.